Evidence map›Paper›PMID 39814321›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics.

Bruna Fernandes, Colleen P Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Dale O Kiesewetter, Lixin Lang, Edmondson Elijah, Rolf Swenson, Peter L Choyke and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bruna FernandesMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Colleen P OlkowskiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Behnaz GhaemiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Falguni BasuliChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD 20850, USA.
Jianfeng ShiChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD 20850, USA.
Dale O KiesewetterMolecular Tracer and Imaging Core Facility, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA.
Lixin LangMolecular Tracer and Imaging Core Facility, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA.
Edmondson ElijahMolecular Histopathology Lab, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD 21701, USA.
Rolf SwensonChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD 20850, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Frank I LinMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Orit JacobsonMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: orit.jacobsonweiss@nih.gov.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Intramural NIH HHS Z99 CA999999NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

B7-H3, an immunomodulatory protein overexpressed in many cancers, is associated with tumor aggressiveness and poor prognosis, making it a crucial target for imaging to elucidate its role in cancer progression and guide therapeutic interventions. This study employed PET imaging to investigate the in vivo delivery and pharmacokinetics of two anti-B7-H3 antibodies, Ab-1 and Ab-2, in mouse xenograft models with varying B7-H3 expression levels. The antibodies were radiolabeled with [

Indexed as

Antibodies, MonoclonalB7 AntigensNeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMice, NudePositron-Emission TomographyRadioisotopesTissue DistributionZirconiumAntibodies, MonoclonalB7 AntigensCD276 protein, humanRadioisotopesZirconiumZirconium-89Antibody pharmacokineticsB7-H3Matrix metalloproteinasesPET imagingZirconium-89 labeling

Identifiers

PMID39814321
PMCPMC11830545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.